US EditionEXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - GT Biopharma (NASDAQ:GTBP)
Summary by Benzinga
1 Articles
1 Articles
All
Left
Center
1
Right
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - GT Biopharma (NASDAQ:GTBP)
GT Biopharma, Inc. (NASDAQ:GTBP) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is a second-generation TriKE therapeutic targeting relapsed or refractory CD33-expressing hematologic malignancies. GT Biopharma specializes in immuno-oncology therapies using its proprietary TriKE NK cell engager platform and holds an exclusive globa…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage